Results 91 to 100 of about 58,962 (264)

T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam, M Figura, J Heyer, S Lieber, M Huber, KL Loveland, HC Schuppe, Daniela Fietz   +7 more
wiley   +1 more source

Detecting Hepatitis B Surface Antigen Mutants

Emerging Infectious Diseases, 2006
Hepatitis B viral mutants can emerge in patients as a result of selection pressure from either immune response or treatment options. Mutations that occur within the immunodominant epitopes of hepatitis B surface antigen (HBsAg) allow mutant virus to propagate in the presence of a neutralizing immune response, while wild-type virus is reduced to ...
openaire   +3 more sources

Short Inter‐Treatment Interval Treatment With Artificial Liver Support System Reduces 90‐Day Transplant‐Free Mortality in Patients With Hepatitis B Virus–Related Acute‐On‐Chronic Liver Failure: A Retrospective Observational Study

Artificial Organs, EarlyView.
ALSS short inter‐treatment interval treatment (patients received two ALSS treatments within 48 h) correlates with improved liver function and 90‐day transplant‐free survival of HBV‐ACLF. This result provides a certain theoretical basis for the timing and time interval of ALSS for HBV‐ACLF, enriches the models and contents of ALSS treatment for HBV‐ACLF,
Jingjie Fu, Fang Chen, Wenfeng Yang, Ting Chen, Jian Xu   +4 more
wiley   +1 more source

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

Acta Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz, Raz Somech, Dan Dominissini, Nathan Keller, Efrat Dresner, Michal Paret, Gilad Sherman, Guy Katzenellenbogen, Elina Gelman, Keren Asraf, Ram Doolman, Atar Lev, Amos J. Simon, Helly Vernitsky, Assaf Barg, Hana Golan, Amos Toren, Michal Stein   +17 more
wiley   +1 more source

Hepatitis B Surface Antigen Testing [PDF]

Infection Control, 1985
openaire   +2 more sources

Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D

Alimentary Pharmacology &Therapeutics, EarlyView.
Bulevirtide increases bile acid levels in most patients; however, changes in bile acids do not predict virological response or adverse events, nor do they reflect treatment adherence. After discontinuation of bulevirtide, bile acid levels rapidly decline.
Marlene Hintersteininger, Michael Schwarz, Philipp Schwabl, Lukas Hartl, Lorenz Balcar, Benedikt Silvester Hofer, Georg Kramer, Christian Sebesta, Paul Thöne, Patrik Attalla, Michael Gschwantler, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Mathias Jachs   +14 more
wiley   +1 more source

A Multivalent mRNA Therapeutic Vaccine Exhibits Breakthroughs in Immune Tolerance and Virological Suppression of HBV by Stably Presenting the Pre-S Antigen on the Cell Membrane

Pharmaceutics
Background/Objectives: In chronic hepatitis B infection (CHB), the hepatitis B surface antigen (HBsAg) continuously exhausts the hepatitis B surface antibody (HBsAb), which leads to the formation of immune tolerance.
Shang Liu, Jie Wang, Yunxuan Li, Muhan Wang, Pei Du, Zhijie Zhang, Wenguo Li, Rongchen Sun, Mingtao Fan, Meijia Yang, Hongping Yin   +10 more
doaj   +1 more source

Temporal Association Between COVID‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis

Alimentary Pharmacology &Therapeutics, EarlyView.
In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi, Allison Carroll, Vy H. Nguyen, Megan Michta, Xuan Q. Zhang, Young‐Suk Lim, Raymond T. Chung   +6 more
wiley   +1 more source

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, EarlyView.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source

Sulfated lactosyl archaeol (SLA) archaeosomes as a vaccine adjuvant

Human Vaccines & Immunotherapeutics
Archaeosomes are liposomes traditionally comprised of total polar lipids or semi-synthetic glycerolipids of ether-linked isoprenoid phytanyl cores with varied glycol- and amino-head groups. We have developed a semi-synthetic archaeosome formulation based
Bassel Akache, Michael J. McCluskie
doaj   +1 more source